Currently out of the existing stock ratings of David Steinberg, 121 are a BUY (83.45%), 24 are a HOLD (16.55%).

David Steinberg

Work Performance Price Targets & Ratings Chart

Analyst David Steinberg, carries an average stock price target met ratio of 64.87% that have a potential upside of 27.61% achieved within 232 days. Previously, David Steinberg worked at JEFFERIES.

David Steinberg’s has documented 275 price targets and ratings displayed on 25 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on BHC, Bausch Health Companies at 20-Sep-2023.

Wall Street Analyst David Steinberg

Analyst best performing recommendations are on SGNT (SAGENT PHARMACEUTICALS).
The best stock recommendation documented was for SUPN (SUPERNUS PHARMACEUTICALS) at 6/15/2020. The price target of $24 was fulfilled within 1 day with a profit of $0.93 (4.03%) receiving and performance score of 40.31.

Average potential price target upside

of $63.39 (17.76%) on NKTR (NEKTAR THERAPEUTICS).
of $37.55 (34.23%) on JAZZ (JAZZ PHARMACEUTICALS PLC).
of $15.22 (90.07%) on COLL (COLLEGIUM PHARMACEUTICAL).

ACRS Aclaris Therapeutics AKRX Akorn AMPH Amphastar P BHC Bausch Health Companies CORI Corium International HZNP Horizon Pharma PLC JAZZ Jazz Pharmaceuticals PLC NKTR Nektar Therapeutics PRGO Perrigo Company PLC SUPN Supernus Pharmaceuticals TEVA Teva Pharma Industries Ltd ADR ZTS Zoetis INSY INSYS Therapeutics PCRX Pacira Pharmaceuticals AGN Allergan plc COLL Collegium Pharmaceutical OPTN OptiNose OSMT Osmotica Pharmaceuticals plc MNLO Menlo Therapeutics PHAT Phathom Pharmaceuticals RVLP RVL Pharmaceuticals PLC OCUL Ocular Therapeutix SGNT Sagent Pharmaceuticals VRCA Verrica Pharmaceuticals XERS Xeris Pharmaceuticals

Show more stocks

Analyst name

Rating

Rating initiation date

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score